论文部分内容阅读
目的:比较埃索美拉唑三联与奥美拉唑三联疗法治疗幽门螺杆菌(Hp)阳性复发性消化性溃疡的临床疗效。方法:将90例经内镜诊断并检测证实Hp阳性的复发性消化性溃疡患者随机分为两组。A组(45例):埃索美拉唑20 mg+羟氨苄青霉素1g+黄连素300 mg,每日2次,共7 d;B组(45例):奥美拉唑20 mg+羟氨苄青霉素1 g+克拉霉素500 mg,每日2次,共7 d、疗程结束4周后复查胃镜并检测Hp,观察腹痛缓解率、溃疡愈合率、Hp根除率及用药后的不良反应等。结果:埃索美拉唑组第1天和第2天腹痛缓解率分别为34.6%和59.6%,高于奥美拉唑组的17.3%和38.5%(P<0.05)。埃索美拉唑组和奥美拉唑组溃疡愈合率分别为92.3%和88.5%,Hp根除率分别为88.5%和82.7%,差异无显著性(P>0.05)。两组用药后不良反应少,有较好的安全性、结论:埃索美拉唑三联疗法治疗Hp阳性的复发性消化性溃疡安全有效,腹痛缓解速度优于奥美拉唑三联疗法。
Objective: To compare the clinical efficacy of esomeprazole triple therapy and omeprazole triple therapy in the treatment of Hp-positive recurrent peptic ulcer. Methods: Ninety patients with recurrent peptic ulcer diagnosed by positive endoscopy and confirmed by Hp were randomly divided into two groups. Group A (45 cases): esomeprazole 20 mg + amoxicillin 1 g + berberine 300 mg twice daily for 7 days; group B (45 cases): omeprazole 20 mg + amoxicillin 1 g + Clarithromycin 500 mg twice a day for 7 days. The endoscopy was performed 4 weeks after the end of treatment and the Hp was examined. The rates of abdominal pain relief, ulcer healing, Hp eradication rate and adverse reactions after treatment were observed. Results: The rates of abdominal pain relief on day 1 and day 2 were 34.6% and 59.6% in esomeprazole group, respectively, which were higher than those in omeprazole group (17.3% and 38.5%, P <0.05). The healing rates of ulcer in esomeprazole group and omeprazole group were 92.3% and 88.5%, respectively, and the eradication rates of Hp were 88.5% and 82.7%, respectively, with no significant difference (P> 0.05). Two groups of adverse reactions after treatment with less, good safety, Conclusion: esomeprazole triple therapy Hp-positive recurrent peptic ulcer is safe and effective, abdominal pain relief better than omeprazole triple therapy.